INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE STUDY LIBRARY

Clinical trial / 1986

In long-term follow-up of the Coronary Drug Project, prior niacin treatment reduced all-cause mortality by 11% compared with placebo.

The Coronary Drug Project evaluated the long-term efficacy and safety of five lipid-influencing drugs versus placebo in 8,341 men with previous myocardial infarction. At trial termination, niacin modestly decreased nonfatal recurrent myocardial infarction but not total mortality. After a mean follow-up of 15 years (nearly 9 years post-trial), all-cause mortality in the niacin group was 11% lower than in the placebo group (52.0% vs. 58.2%; p = 0.0004), while mortality in other drug groups was similar to placebo.

Study type
Randomized controlled trial follow-up
Who was studied
8,341 men aged 30 to 64 years with previous myocardial infarction
What was measured
All-cause mortality and recurrent nonfatal myocardial infarction

THE PAPER

Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin.

Canner PL, Berge KG, Wenger NK, Stamler J, Friedman L, Prineas RJ, Friedewald W. J Am Coll Cardiol, 1986.

PubMed 3782631 ↗DOI 10.1016/s0735-1097(86)80293-5 ↗

Heart & arteries

This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.